Drug Toxicities in Second-Line Treatment of Chronic Myeloid Leukemia

被引：0
|
作者：
Datoguia, Tarcila S. [1 ]
Silva, Hugo R. C. [1 ]
Junior, Amauri M. C. R. [1 ]
Oliveira, Jose Salvador [1 ]
Conchon, Monika [1 ]
机构：
[1] Hosp Santa Marcelina, Hematol, Sao Paulo, Brazil
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Chronic myeloid leukemia: Second-line drugs of choice
    Gambacorti-Passerini, Carlo
    Aroldi, Andrea
    Cordani, Nicoletta
    Piazza, Rocco
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (01) : 67 - 75
  • [2] Optimizing second-line therapy for chronic myeloid leukemia
    Raja, T.
    INDIAN JOURNAL OF CANCER, 2012, 49 (01) : 46 - 56
  • [3] Recommendations on monitoring and second-line therapy for chronic myeloid leukemia
    Hochhaus, A.
    Overkamp, F.
    Lange, T.
    Mohr, A.
    Ottmann, O.
    Coutre, P.
    Haferlach, T.
    ONKOLOGE, 2010, 16 (07): : 701 - 708
  • [4] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia
    Yood, Marianne Ulcickas
    Oliveria, Susan A.
    Cziraky, Mark
    Hirji, Ishan
    Hamdan, Muhammad
    Davis, Catherine
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (02) : 213 - 219
  • [5] Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase
    陈怡琳
    ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (03) : 181 - 181
  • [6] Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure
    Enrique Santos-Macias, Juan
    Baez de la Fuente, Enrique
    Salas-Delgado, Arnoldo
    GACETA MEDICA DE MEXICO, 2016, 152 (03): : 334 - 338
  • [7] Treatment of Chronic Myeloid Leukemia Following Imatinib Resistance: A Nursing Guide to Second-Line Treatment Options
    Bauer, Stephanie
    Romvari, Edie
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2009, 13 (05) : 523 - 534
  • [8] PRIOR THERAPY WITH INTERFERON IMPROVES THE RESULTS OF SECOND-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB
    Kotlyarchuk, K.
    Lukjanova, A.
    Lukavetskyy, L.
    Karol, Y.
    Danysh, O.
    Lozynska, M.
    Maslyak, Z.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 541 - 542
  • [9] Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
    Mahon, Francois-Xavier
    Boquimpani, Carla
    Kim, Dong-Wook
    Benyamini, Noam
    Clementino, Nelma Cristina D.
    Shuvaev, Vasily
    Ailawadhi, Sikander
    Lipton, Jeffrey Howard
    Turkina, Anna G.
    De Paz, Raquel
    Moiraghi, Beatriz
    Nicolini, Franck E.
    Dengler, Jolanta
    Sacha, Tomasz
    Takahashi, Naoto
    Fellague-Chebra, Rafik
    Acharya, Sandip
    Wong, Stephane
    Jin, Yu
    Hughes, Timothy P.
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (07) : 461 - +
  • [10] Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
    Breccia, Massimo
    Abruzzese, Elisabetta
    Castagnetti, Fausto
    Bonifacio, Massimiliano
    Gangemi, Domenica
    Sora, Federica
    Iurlo, Alessandra
    Luciano, Luigiana
    Gozzini, Antonella
    Gentile, Massimo
    Bocchia, Monica
    Luzi, Debora
    Maggi, Alessandro
    Sgherza, Nicola
    Isidori, Alessandro
    Crugnola, Monica
    Pregno, Patrizia
    Scortechini, Anna Rita
    Capodanno, Isabella
    Pizzuti, Michele
    Foa, Robin
    ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1577 - 1580
12345